Skip to content

Study · Randomized controlled trial · n = 465 · 2007

2 results

A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93.

Kaufmann M, Graf E, Jonat W, Eiermann W, Vescia S, Geberth M, Conrad B, Gademann G, Albert US, Loibl S, von Minckwitz G, Schumacher M

European journal of cancer (Oxford, England : 1990)25 Sept 2007Cited by 18 (Europe PMC)

PMID17897821 (opens in a new tab)DOI10.1016/j.ejca.2007.08.012 (opens in a new tab)PepBankPUB-17897821
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In HR-negative breast cancer, goserelin did not improve event-free survival versus control (HR 1.01; 95% CI 0.72-1.42; P=0.97).

    In plain wordsIn HR-negative breast cancer, goserelin did not improve event-free survival compared with no further treatment after chemotherapy.

    Peptide
    Goserelin
    Outcome
    No significant changeEvent-free survival in HR-negative patients
    Study

    n = 465

    Comparator
    No further treatment after chemotherapy
    Outcome group
    Cancer Survival · Cancer
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio for event-free survival
    1.01 ratio
    HR-negative, goserelin versus control
    95% CI of hazard ratio
    0.72 to 1.42 ratio
    HR-negative, goserelin versus control

    Source sentences

    Summary
    The adjusted estimated hazard ratio for event-free survival in HR-negative patients was 1.01 (goserelin versus control, 95% confidence interval [CI] 0.72-1.42, P=0.97) and 0.77 in HR-positive patients (95% CI 0.47-1.24, P=0.27).
    2 context sentences
    Summary · context
    GABG-IV B-93 is a prospective, randomised study comparing goserelin (n=384) with no further treatment (n=392) in hormone receptor (HR)-negative breast cancer patients (n=465)
    Summary · context
    After completion of the ZEBRA trial the study was amended to enrol also HR-positive patients with 1-9+LN (n=311).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In HR-positive breast cancer, goserelin did not improve event-free survival versus control (HR 0.77; 95% CI 0.47-1.24; P=0.27).

    In plain wordsIn HR-positive breast cancer, goserelin did not improve event-free survival compared with no further treatment after chemotherapy.

    Peptide
    Goserelin
    Outcome
    No significant changeEvent-free survival in HR-positive patients
    Study

    n = 311

    Comparator
    No further treatment after chemotherapy
    Outcome group
    Cancer Survival · Cancer
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio for event-free survival
    0.77 ratio
    HR-positive, goserelin versus control
    95% CI of hazard ratio
    0.47 to 1.24 ratio
    HR-positive, goserelin versus control

    Source sentences

    Summary
    The adjusted estimated hazard ratio for event-free survival in HR-negative patients was 1.01 (goserelin versus control, 95% confidence interval [CI] 0.72-1.42, P=0.97) and 0.77 in HR-positive patients (95% CI 0.47-1.24, P=0.27).
    2 context sentences
    Summary · context
    GABG-IV B-93 is a prospective, randomised study comparing goserelin (n=384) with no further treatment (n=392) in hormone receptor (HR)-negative breast cancer patients (n=465)
    Summary · context
    After completion of the ZEBRA trial the study was amended to enrol also HR-positive patients with 1-9+LN (n=311).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.